15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Harmony Biosciences Holdings, 3 rate it Buy or better, 3 sit at Hold, and 1 rate it Sell or worse, a hold consensus. Targets span $28.00 to $55.00, a moderate spread. The average target of $39.14 sits 9% above the current $36.01. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.22 next quarter toward $6.02 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Hold
Strong Buy00%
Buy343%
Hold343%
Sell114%
Strong Sell00%
Based on 7 analysts giving stock ratings to Harmony Biosciences Holdings.
As of Jul, 3 of 7 firms rate HRMY a Buy (3 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
HRMY EPS & revenue forecast
EPS · NEXT QUARTER
$1.22
Range $0.93 – $1.46 · 3 analysts · +13% YoY
Next period, 3 analysts expect Harmony Biosciences Holdings to earn $1.22 a share (range $0.93 – $1.46), versus $1.08 a year earlier. Full-year consensus is $4.50, growing to $6.02 the year after.
REVENUE · NEXT QUARTER
$272.0M
Range $263.9M – $276.0M · 3 analysts · +14% YoY
Revenue is expected to reach $272.0M (range $263.9M – $276.0M), +13.6% year-over-year. Full-year consensus is $1.0B, rising to $1.2B next year.
Top analysts covering Harmony Biosciences Holdings
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HRMY.
#1
Ami Fadia
Needham · Rank #90
Buy
$45.00+25.0% to target
Overall win rate
46%
+ Follow
#2
David Amsellem
Piper Sandler · Rank #95
Buy
$46.00+27.7% to target
Overall win rate
50%
+ Follow
#3
Jason Gerberry
B of A Securities · Rank #136
Sell
$28.00-22.2% to target
Overall win rate
46%
+ Follow
#4
Charles Duncan
Cantor Fitzgerald · Rank #188
Buy
$50.00+38.9% to target
Overall win rate
42%
+ Follow
#5
Patrick R. Trucchio
HC Wainwright & Co. · Rank #203
Buy
$55.00+52.7% to target
Overall win rate
35%
+ Follow
HRMY stock forecast FAQ
What is HRMY's average 12-month price target?+
The 7 analysts with a live target average $39.14 for Harmony Biosciences Holdings over the next 12 months, ranging from a $55.00 high to a $28.00 low.
Is HRMY stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 7 analyst ratings, 3 are Buy or Strong Buy, 3 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for HRMY?+
The Street-high target is $55.00 (HC Wainwright & Co.), and the Street-low is $28.00 (B of A Securities). The average of all 7 active targets is $39.14.
How many Wall Street analysts cover HRMY?+
7 analysts have an active rating on Harmony Biosciences Holdings, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering HRMY?+
Among analysts who currently cover HRMY, Ami Fadia of Needham has the strongest overall Quantellect track record (Rank #90). Their current call is Buy with a $45.00 target.
What is Harmony Biosciences Holdings's projected EPS for next quarter?+
The consensus estimate is $1.22 per share (range $0.93 – $1.46) across 3 analysts. Full-year EPS is projected at $4.50, rising to $6.02 the following year.
How much revenue is Harmony Biosciences Holdings expected to report next quarter?+
Consensus revenue is $272.0M (range $263.9M – $276.0M). Full-year revenue is projected at $1.0B, growing to $1.2B next year.
Have analysts been upgrading or downgrading HRMY lately?+
As of Jul, 3 of 7 firms rate HRMY a Buy (3 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HRMY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
